Navigation Links
Access Pharmaceuticals Retains Edelman as Public Relations Firm
Date:8/5/2011

DALLAS and NEW YORK, Aug. 5, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has hired Edelman, the leading full service global public relations firm, to support its media outreach initiatives.  Edelman will assist Access in implementing a media communications outreach program primarily aimed at introducing MuGard and building awareness of its ability to treat oral mucositis, a potentially debilitating disease which can cause painful inflammation and lesions of the mucous membranes lining the mouth and GI tract.

"Edelman has a great track record in conveying the value of company pipelines to a broad range of media outlets," said Jeffrey Davis, Chief Executive Officer, Access Pharmaceuticals, Inc.  He continued, "We believe we are at the right time in the Access story and the commercialization of MuGard to expand our reach in within trade and consumer publications.   As we continue to execute on our strategy of growing the MuGard brand, capitalizing on Edelman's strategic skills, creativity and global reach to communicate the benefit and control it provides cancer patients will be key in achieving our MuGard education and communications objectives."

Bruce Hayes, general manager of Health for Edelman in the company's New York office stated, "We are pleased that Access has made the decision to join our portfolio of health clients.  An emerging player in the cancer supportive care industry, Access is helping patients who suffer from oral mucositis. We are confident that our public engagement strategies will assist in building the MuGard brand and raising Access' visibility among its key audiences."

About EdelmanEdelman is the world's largest independent public relations firm, with wholly-owned offices in 53 cities and 3,700 employees worldwide. Edelman was named Advertising Age's top-ranked PR firm of the decade and one of its "2010 A-List Agencies" and "2010 Best Places to Work;" PRWeek's "2011 Large PR Agency of the Year" and "2009 Agency of the Year;" European Excellence Awards' "2010 Agency of the Year;" Holmes Report's "Agency of the Decade" and "2009 Asia Pacific Consultancy of the Year;" and among Glassdoor's top five "2011 Best Places to Work." Visit http://www.edelman.com for more information.

About Access Pharmaceuticals, Inc.Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. WeinbergerDirector of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unrestricted Access to Advanced Imaging a Top Priority for Consumers
2. Elsevier Launches Next Generation Codifa, Providing Italian Doctors with Real Time Access to Critical Drug Information
3. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
4. Diverse Elders Coalition Urges President Obama, Congressional Leaders to Protect Seniors Access to Home Healthcare
5. Concentric Medical Launches DAC® 070, A New Distal Access Catheter
6. Study Published in Journal of Vascular Surgery Confirms Superiority of Artegraft BCA to Cuffed ePTFE for Hemodialysis Access
7. Access Pharmaceuticals MuGard Included in TRICARE Prescription Drug Coverage
8. Pharmacy Choice & Access Now Coalition Urges Full Implementation of Senate Bill 7
9. Access Pharmaceuticals MuGard Added to CVS Caremarks Pharmacy Benefit Network
10. Kimberly-Clark Launches KimVent Multi-Access Port Closed Suction System
11. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):